All News
Subclinical Synovitis in Psoriasis Portends Future Psoriatic Arthritis
It is estimated that nearly 30% of psoriasis patients will develop psoriatic arthritis (PsA). This prevalence was studied by performing MRI scans on asymptomatic psoriasis (n=56) and 30 control patients without arthritis.
Read ArticleCurbside Consults - February 2016
The following is a collection of cases presented to me by rheumatology colleagues. Each has a challenging therapeutic or safety issue. Answers are based on experience with references from literature and guidelines.
Read ArticleCBC Hidden Pearls
CBC…it’s easy as 123! The complete blood count (aka, CBC) is the most routine, but indispensable, of all medical assessments.
Read ArticleASAS: MRI Definition of Active Sacroiliitis
Increased use of MRI for diagnosis of spondyloarthritis (SpA) in the last two decades has led to earlier diagnoses and gradual incorporation of MRI into the SpA assessment toolset.
Read ArticleHidradenitis Suppurativa Increases Cardiovascular Event Risk
Hidradenitis suppurativa (HS) is a chronic inflammatory disease affecting exocrine glands with painful abscesses in intertriginous areas.
Read ArticleRWCS 2016 - Updates in AS, PsA and Lupus
Update on Ankylosing Spondylitis and Spondyloarthritis
Read ArticleRWCS 2016 – Rheumatoid Review, Psoriatic Arthritis and Medical Marijuana
The Rheumatology Winter Clinical Symposia launched its 9th annual conference yesterday in Maui. Highlights of this meeting will be covered by RheumNow from Wednesday 2/10 till Saturday 2/13.
Rheumatoid Arthritis Year in Review
Read ArticleFDA Advisory Arthritis Committee Votes to Approve the CT-P13 (infliximab) Biosimilar
On Tuesday February 9th Celltrion presented its biosimilar developmental data to the FDA as they sought approval for their CT-P13 (called Inflectra), a biosimilar of infliximab (Remicade).
Read ArticleFDA Reviews Celltrion's Remicade Biosimilar Today
The arthritis advisory committee of the Food and Drug Administration (FDA) is scheduled to meet today, February 9th to review the efficacy and safety of Celltrion's biosimilar form of infliximab (Remicade) that is currently marketed in other countries.
Read ArticleCochrane Review:NSAIDs Equally Effective for Axial Spondyloarthritis
Until the advent of TNF inhibitor therapy, nonsteroidal antiinflammatory drugs (NSAIDs) were the only effective treatment for ankylosing spondylitis or spondyloarthritis (SpA). More recently, several reports have suggested clinical and radiographic benefits to sustained NSAID use.
Read ArticleNo Significant Increased Risk with TNF Inhibitors During Pregnancy
A population-based study of 1,272,424 live-born infants from Denmark and Sweden examined the prevalence of birth defects among infants born to 683 women with chronic inflammatory disease (inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis)
Read ArticleBiosimilar of Remicade Works in Ankylosing Spondylitis
CT-P13, a biosimilar of infliximab (Remicade), demonstrated comparable and durable efficacy in the treatment of ankylosing spondylitis (AS), a multinational study found.
Read ArticlePALACE 3 Study: Apremilast Shows 52 Wk. Efficacy in Active Psoriatic Arthritis
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibiting conversion of cyclic AMP to AMP, was approved for treatment of psoriatic arthritis (PsA) after showing its efficacy in 16 weeks PALACE 1, 2, and 3 trials in 2014.
Read ArticleMethotrexate Nonadherence is Common
Researchers from Belgium studied patient adherence to MTX (given orally or via injection) in 129 rheumatoid arthritis (RA) patients over a 16-week period using an electronic monitoring system and two validated adherence questionnaires.
Read ArticleFDA Approves Cosentyx for Ankylosing Spondylitis and Psoriatic Arthritis
Cosentyx (secukinumab) was approved by the FDA on 15 January, 2016 for patients with active ankyosing spondylitis (AS) and psoriatic arthritis (PsA).
Read ArticleGame-Changers 2015: Refining Treatment in Arthritis
Widening experience with JAK inhibition for rheumatoid arthritis (RA) and tapering medications among RA patients in remission, along with the success of secukinumab for psoriatic arthritis (PsA), were the most important advances in rheumatology in 2015, according to specialists responding toMedPa
Read ArticleThe Global Prevalence of Spondyloarthritis
SpA is a common disease, but with large variation in reported prevalence estimates, partly explained by differences in demographical and methodological characteristics.
Read ArticleSecukinumab Shows Efficacy in Two Ankylosing Spondylitis Trials
NEJM has published the results of two studies wherein IL-17 inhibition with secukinumab (SEC) was shown to be effective in patients with anklylosing spondylitis.
Read ArticleIncreased Adverse Pregnancy Outcomes in Ankylosing Spondylitis
Although ankylosing spondylitis affects a predominantly male population, the ratio of men to women has declined from 9-10:1 in earlier studies to more recent estimates of 2-3:1 (F:M).
Read ArticleTofacitinib Shows Promise in Alopecia, Eczema and Vitiligo
Tofacitinib has been approved for use in rheumatoid arthritis.
Read Article